{"nctId":"NCT01895855","briefTitle":"Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera","startDateStruct":{"date":"2013-09"},"conditions":["Cholera"],"count":197,"armGroups":[{"label":"PXVX0200","type":"EXPERIMENTAL","interventionNames":["Biological: PXVX0200"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: placebo"]}],"interventions":[{"name":"PXVX0200","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy men or women,\n* age 18 to 45 years inclusive;\n* normal medical history and physical examination; and\n* no clinically significant abnormalities from:\n* urine dipstick for glucose, protein, and blood\n* complete blood count,\n* serum hepatic transaminases,\n* total bilirubin (direct if abnormal),\n* creatinine,\n* electrolytes,\n* albumin, or\n* electrocardiogram.\n* Women must have a negative pregnancy test.\n\nExclusion Criteria:\n\n* travel to a cholera endemic area in the previous 5 years;\n* abnormal stool pattern or regular use of laxatives;\n* history of eating disorders (such as bulimia), anal or rectal disorders, allergy to tetracycline and/or ciprofloxacin;\n* history of cholera or enterotoxigenic E. coli challenge or infection;\n* current or recent antibiotic use;\n* pregnancy or nursing;\n* positive serology for HIV, hepatitis B antigen, or hepatitis C;\n* any immunosuppressive medical condition;\n* history of hospitalization for psychiatric illness or use of specific psychiatric drugs.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significantly greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) diarrhea.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]}]},{"type":"PRIMARY","title":"% of Participants With Moderate to Severe Diarrhea","description":"Determine whether a single dose of PXVX0200 provides significant greater protection than placebo against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination. The primary endpoint was the occurrence of moderate or severe (\\>/= 3 liters) of diarrhea.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Weight of Diarrheal Stools Following the 10 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 10 day cholera challenge.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309","spread":null},{"groupId":"OG001","value":"4524","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Weight of Diarrheal Stools Following the 90 Day Cholera Challenge","description":"Total weight (converted to volume) per subject of diarrheal stools measured from subjects with diarrhea following the 90 day cholera challenge.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"603","spread":null},{"groupId":"OG001","value":"4524","spread":null}]}]}]},{"type":"SECONDARY","title":"% of Participants With Diarrhea of Any Severity Following a 10 Day Cholera Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 10 day cholera challenge.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]}]},{"type":"SECONDARY","title":"% of Participants With Diarrhea of Any Severity Following a 90 Day Challenge","description":"Incidence of mild or worse (any severity) diarrhea following the 90 day cholera challenge.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]}]},{"type":"SECONDARY","title":"% of Participants With Fever Following the 10 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 10 day cholera challenge.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"% of Participants With Fever Following the 90 Day Cholera Challenge","description":"Incidence of mild or worse fever following the 90 day cholera challenge.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Fecal Shedding Following 10 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 10 Day Challenge.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Fecal Shedding Following 90 Day Challenge","description":"Number of days of fecal shedding of wild type V. cholerae following 90 Day Challenge","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"# of Days With Positive Stool Culture Following 10 Day Cholera Challenge","description":"Total number of days with a positive stool culture following the 10 Day Cholera challenge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.20"},{"groupId":"OG001","value":"3.3","spread":"1.01"}]}]}]},{"type":"SECONDARY","title":"# of Days With Positive Stool Culture Following 90 Day Cholera Challenge","description":"Total number of days with a positive stool culture following 90 Day Cholera Challenge","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.41"},{"groupId":"OG001","value":"3.3","spread":"1.01"}]}]}]},{"type":"SECONDARY","title":"% of Participants With Reactogenicity, Diarrhea, Fever or Unsolicited Adverse Events Following Vaccination","description":"Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever following vaccination (through Day 8).\n\nIncidence and severity of unsolicited adverse events following vaccination (through Day 29).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":95},"commonTop":["Fatigue","Upper Respiratory tract infection","Flatulence","Rhinorrhoea","Musculoskeletal pain"]}}}